IOncology

With the discovery of molecular targets and the development of corresponding targeted inhibitors, the treatment of metastatic colorectal cancer (mCRC) is becoming increasingly precise and personalized. At the recent 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Xiujuan Qu from The First Hospital of China Medical University shared the latest advancements in precision treatment for advanced colorectal cancer, including novel therapeutic strategies and the promising role of KRAS G12C inhibitors.

New findings from the DESTINY-Breast12 study, published in Nature Medicine on September 13, 2024, highlight the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC), including patients with…

New insights from the COMET randomized clinical trial, published on December 12, 2024, in JAMA Oncology, offer important evidence on the patient experience in managing low-risk ductal carcinoma in situ…

The impact of long-term toxicity management on patient quality of life is increasingly being recognized in breast cancer treatment. At the recently held 19th St. Gallen Breast Cancer Conference (SGBCC 2025), Dr. Cynthia Villarreal-Garza, Director of Clinic Oncology at the Breast Cancer Center, TecSalud,delivered a presentation titled “Ensuring Long-term Healthy Survival of Breast Cancer Patients.” She pointed out that young breast cancer patients, due to the high intensity and long duration of their treatment, face a number of unique toxicity issues that not only affect their physical health but also have a profound impact on their psychological well-being, social functioning, and overall quality of life. To monitor and intervene in these long-term toxicities, Professor Villarreal-Garza proposed the application of “evidence-based approaches for healthy living” and the use of remote monitoring applications to effectively manage toxicities and improve patient quality of life.

On the occasion of the 2025 POST-ASCO GI and the 2nd Oncology Basic and Translational Research Forum, Oncology Frontier conducted an in-depth interview with the event’s Executive Chair, Dr. Yanhong…

Breast cancer is one of the most common malignant tumors among women worldwide, and its treatment has been a key focus in the medical field. With ongoing research, significant progress…

In recent years, clinical research in China’s breast cancer field has made significant strides, particularly in the area of new drug clinical research. A series of groundbreaking studies have been…

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco, California, from February 13 to 15. It attracted top experts and scholars in the field of urology from around the world. At this conference, Oncology Frontier invited Dr. Philip Kwong from The University of Hong Kong to share his insights on precision testing and individualized management in metastatic castration-resistant prostate cancer (mCRPC). He believes that precision testing and continuous monitoring are crucial for optimizing treatment strategies for mCRPC, and he particularly emphasized the key role of genetic testing in assessing homologous recombination repair (HRR) status. His insights not only provide important guidance for clinical practice but also bring new perspectives to the individualized treatment of mCRPC.

Radioligand Therapy (RLT) is an innovative treatment modality in the field of prostate cancer, enriching the therapeutic options. With further research, the personalized application of RLT and its combination with other therapies will become an important direction for the future treatment of prostate cancer. Oncology Frontier invited Dr. Angela Jia, an expert in radiation oncology at the UH Seidman Cancer Center, to share her insights on the role and future potential of RLT and local radiotherapy in the treatment of prostate cancer.

The emergence and evolution of natural orifice specimen extraction surgery (NOSES) in colorectal oncology marks a significant milestone in the journey toward scarless surgery. Since Professor Xishan Wang’s team first…